Teladoc Health Investor Presentation — December 2021

Document content

4Q-21 Quarterly Results

••4Q Revenue of $554M grew 45% y/y

•4Q Adjusted EBITDA(1)of $77.1M grew 53% y/y

•FY-21 Operating Cash Flow of $194M

•FY-22 Revenue guidance range $2.55B to $2.65B

•1Q-22 Revenue guidance range $565M to $571M

•FY-22 Adj. EBITDA guidance range $330M to $355M

•1Q-22 Adj. EBITDA guidance range $51M to $55M

1. See reconciliation of GAAP to non -GAAP measures immediately following this presentation.$50.4$77.1

$0$10$20$30$40$50$60$70$80$90

4Q-20 4Q-21Adj. EBITDA ($ millions)(1)

$0$100$200$300$400$500$600

4Q-20 4Q-21Revenue ($ millions)

1.See reconciliation of GAAP to non -GAAP measures immediately following this presentation+53%

y/yAccess Fee Revenue ($ millions) (1)Visit Fee Revenue ($ millions) (1)

$0$100$200$300$400$500

$0$10$20$30$40$50$60$70$80

1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities

were primarily reflected based on the location of operations. In addition, certain activities related to our international op erations are now reflected in visit revenues versus access fee revenues. Prior period

amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have be en updated.$51$71

$0$10$20$30$40$50$60$70$80

$0$100$200$300$400$500$600

4Q-20 4Q-21U.S. Revenue ($ millions) (1)International Revenue ($ millions) (1)

1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities

were primarily reflected based on the location of operations. In addition, certain activities related to our international op erations are now reflected in visit revenues versus access fee revenues. Prior period

amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have be en updated.U.S. Paid Members (millions) Revenue ($ millions) (1)

Avg US Revenue per Member (1) (2) Chronic Care Enrollment (000s)

1. During the fourth quarter of 2021, Teladoc Health refined its definition of international revenues to reflect all internation al revenues based on location of the customer. Previously, direct to consumer activities were

primarily reflected based on the location of operations. In addition, certain activities related to our international operati onsare now reflected in visit revenues versus access fee revenues. Prior period amounts have